Mechanisms of HIV Drug Resistance Session Posters

Resistance to HIV-1 entry inhibitors may occur by multiple molecular mechanisms
CJ Petropoulos

Mutations in HIV-1 RNase H domain confer high-level resistance to nucleoside reverse transcriptase inhibitors and provide novel insights into the mechanism of nucleotide excision-mediated drug resistance
VK Pathak

Misincorporation of thymidine analogues can increase drug susceptibility
M Götte

Effects of mutations associated with suppression of zidovudine resistance in HIV-1 reverse transcriptase on removal of tenofovir from blocked primer/template
J Lennerstrand

Kinetic mechanism of HIV-1 reverse transcriptase catalyzed AZT excision
N Sluis-Cremer

Selective primer unblocking of carbovir, lamivudine, tenofovir and zidovudine by wild-type HIV reverse transcriptase with nucleotide and deoxynucleotide triphosphates
ER Lanier

The selective advantage of AZT-resistance mutations can be demonstrated in vitro but is suppressed at high levels of PPi
AJ Smith

Bisphosphonate inhibitors of nucleoside reverse transcriptase inhibitor excision
MA Parniak

Impaired rescue of chain-terminated DNA synthesis associated with the L74V mutation in HIV-1 reverse transcriptase
MA Wainberg

Thermodynamic analysis of capravirine binding to HIV reverse transcriptase and inhibition of DNA polymerase and RNase H activities
K Klumpp

Novel mechanisms involved in non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance of both the subtype D HIV-1 isolate and reverse transcriptase derived from a drug-naive Ugandan
H Baird

Structural studies of benzophenone/HIV-1 RT complexes: insights into the potency of the next generation NNRTIs against WT and mutant HIV-1
DK Stammers

Dinucleoside polyphosphates are novel inhibitors of HIV-1 reverse transcriptase with increased potency against enzymes containing AZT-resistance mutations
P Meyer

Natural resistance of HIV-2 to zidovudine
JG García-Lerma

Potential reversion pathways of Tyr 215 to Thr in HIV-1 reverse transcriptases having a dipeptide insertion between codons 69 and 70: consequences for zidovudine and stavudine resistance
L Menéndez-Arias

The HIV-1 RT mutation H208Y combined with T215Y causes hypersusceptibility to efavirenz
SA Clark

Effect of cell cycle arrest on HIV susceptibility to RT inhibitors
F Clavel

Novel HIV drug resistance mechanism leading to protease inhibitor (PI) resistance in response to a high genetic barrier PI in vitro
M Nijhuis

‘Wide open’ 1.3 Å structure of the multidrug-resistant HIV-1 protease represents a novel drug target
LC Kovari

Susceptibility to saquinavir and atazanavir in highly protease inhibitor (PI) resistant HIV-1 is caused by lopinavir-induced drug resistance mutation L76V
H Walter

Resistance-related polymorphisms in HIV-1 non-B subtype protease influence the resistance pathway and amplify resistance to protease inhibitors
SH Qari

Predictors of selection of K65R: tenofovir use and lack of TAMs
L Valer

In vitro antiviral interactions among tenofovir, abacavir, lamivudine and didanosine
CL Tremblay

Prevalence of HIV-1 GAG cleavage site mutations in patients failing protease inhibitors in the GART Study (CPCRA 046)
JD Baxter

No evidence for stavudine resistance due to nevirapine-selected mutation Y181C in HIV-1 reverse transcriptase in a large
genotype/phenotype database
K Korn